Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer On March 20, 2026, the core compound patent for semaglutide held by the Danish pharmaceutical company Novo Nordisk will officially expire in China
Because the resulting synthetic molecule can be fully characterized through structural analysis (unlike complex biologics), regulators can treat it as a conventional generic drug rather than a biosimilar
Pre-blended Reconstitution Spec Vial size Value 20 mg total (10 mg BPC-157 + 10 mg TB-500) Spec BAC water added Value 2.0 mL Spec Total concentration Value 10 mg/mL (5 mg/mL each compound) Spec 10 units (0.10 mL) delivers Value 0.5 mg BPC-157 + 0.5 mg TB-500 Spec 20 units (0.20 mL) delivers Value 1.0 mg BPC-157 + 1.0 mg TB-500 Spec Doses per vial (1.0 mg/day) Value ~20 days Concentration scales linearly with BAC water volume 3.0 mL gives ~6.7 mg/mL total (3.33 mg/mL each)
Low-level laser therapy (LLLT) : Improves mitochondrial function and complements peptide-induced cellular activation
Cash Price for Ozempic, Wegovy, and Rybelsus (Without Insurance) The manufacturer, Novo Nordisk, pursued separate FDA approvals to cater to different needs
